eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2006
vol. 3
 
Share:
Share:
abstract:

Anestezjologia i intensywna terapia
Coronary artery bypass grafting in abciximab: treated non-elective patients

Rafał Drwiła
,
Marcin Ziętkiewicz
,
Dariusz Plitzner
,
Bogusław Kapelak
,
Krzysztof Wróbel
,
Paweł Moncznik
,
Maria Śnieżek-Maciejewska
,
Jerzy Sadowski
,
Janusz Andres

Kardiochir Torakochir Pol 2006; 3, 2: 187-193
Online publish date: 2006/08/31
View full text Get citation
 
Background: Between January 2002 and September 2005 abciximab was used in 1150 patients with a wide spectrum of cardiological interventions in our haemodynamic department. Among them 48 were operated on for cardiopulmonary bypass (CPB). 12 were operated on in non-elective mode not later than 14 days after abciximab use. Material and methods: The group of 12 patients operated on in non-elective mode during which the potential effect of abciximab was compared with the group of 80 coronary patients operated on also non-electively. Both groups received heparin and aspirin during the preoperative period. We analyzed postoperative drainage and use of blood and blood products. Results: Blood loss and transfusions of packed red cells and fresh frozen plasma were similar in both groups. The volume of transfused platelets was higher in the abciximab-treated group (p<0.01). Conclusions: Risk of post-operative bleeding is similar in non-elective patients receiving heparin/aspirin after abciximab compared to the group treated with heparin/aspirin alone. There is still no gold-standard test for platelet function assessment available.
keywords:

cardiopulmonary bypass, abciximab

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.